OptEase Retrievable Inferior Vena Cava Filter: Initial Multicenter Experience
OptEase Retrievable Inferior Vena Cava Filter: Initial Multicenter Experience
复制标题
OptEase 可回收下腔静脉过滤器：初步多中心体验
DOI：
10.1258/rsmvasc.13.5.286
复制
发表时间：
2005
期刊：
影响因子：
1.1
通讯作者：
E. Wellons
中科院分区：
文献类型：
--
作者：
D. Rosenthal;J. Swischuk;Sidney A. Cohen;E. Wellons
本文的目的是描述我们使用可回收的OptEase下腔静脉滤器(IVCF)(佛罗里达州迈阿密湖科迪斯公司)预防肺血栓(PE)的经验。40名暂时存在PE风险的患者(24名男性，年龄范围15-85岁，平均年龄38岁)在两个机构接受了OptEase IVCF的置入和取回。11例患者接受滤器植入，然后在下腔静脉(IVC)重新定位以延长植入时间。所有患者在取材后被随访24小时，并根据医生的判断进行额外的随访。40例患者成功置入滤器。两名接受血管内超声引导以部署滤器的患者，由于不小心放置在右侧髂总静脉，需要在24小时内重新定位滤器。所有40名患者都成功地进行了过滤器检索，没有不良事件发生。未行IVCF复位者，术后恢复时间为3~48天，平均16.38±7.20天。1例患者在48天成功取材，但所有其他取材经验均在23天内完成。第二种策略涉及植入，在最终取回之前至少重新定位一次。后一种策略发生在11例患者中，首次发作的时间为4~30天，平均为13.82±6.13天。未观察到症状性PE、下腔静脉损伤或狭窄、大量出血、滤器破裂或滤器移位。在这项可行性研究中，OptEase IVCF预防了症状性PE，在植入后48天可以安全地回收或重新定位，并成为抗凝的有效桥梁。在需要延长IVCF放置时间的患者中，OptEase IVCF可以成功地在下腔静脉内重新定位，从而延长了这种可回收IVCF的整体植入时间。
The purpose of this article is to describe our experience with the retrievable OptEase inferior vena cava filter (IVCF) (Cordis Corporation, Miami Lakes, FL) in the prevention of pulmonary embolus (PE). Forty patients (24 men, age range 15–85 years, mean age 38 years) who were at temporary risk of PE underwent insertion and retrieval of the OptEase IVCF at two institutions. Eleven patients were treated with filter implantation and subsequent repositioning in the inferior vena cava (IVC) to extend implantation time. All patients were followed up for 24 hours after retrieval, with additional follow-up at the physician's discretion. Forty patients had successful filter insertion. Two patients who underwent intravascular ultrasound guidance for filter deployment required filter repositioning within 24 hours owing to inadvertent placement in the right common iliac vein. All 40 patients underwent successful filter retrieval with no adverse events. In those patients who did not undergo IVCF repositioning, the time to retrieval ranged from 3 to 48 days (mean ± SD 16.38 ± 7.20 days). One patient had a successful retrieval at 48 days, but all other retrieval experiences were performed within 23 days. The second strategy involved implantation, with repositioning at least once before final retrieval. This latter strategy occurred in 11 patients, and the time to first capture ranged from 4 to 30 days (mean ± SD 13.82 ± 6.13 days). No symptomatic PE, IVC injury or stenosis, significant bleeding, filter fracture, or filter migration was observed. In this feasibility study, the OptEase IVCF prevented symptomatic PE, was safely retrieved or repositioned up to 48 days after implantation, and served as an effective bridge to anticoagulation. In patients who require extended IVCF placement, the OptEase IVCF can be successfully repositioned within the IVC, thereby extending the overall implantation time of this retrievable IVCF.